Logo.png
Ocean Biomedical (NASDAQ: OCEA) Will Host an R&D Update Today on Malaria, and Fibrosis Programs with Scientific Co-founders Jack A. Elias, MD, and Jonathan Kurtis, MD PhD.
14 sept. 2023 08h01 HE | Ocean Biomedical, Inc.
Presentation will be hosted live on Ocean Biomedical’s Youtube Channel at 2:00pm ET Providence, RI, Sept. 14, 2023 (GLOBE NEWSWIRE) -- Ocean Biomedical, Inc. (NASDAQ: OCEA), a next-generation...
Picture1.png
Ocean Biomedical (NASDAQ: OCEA) Announces Notice of Allowance for U.S. Patent Application for Developing “Whole New Class” of Malaria Therapeutics Issued to Scientific Co-founder Dr. Jonathan Kurtis
13 avr. 2023 08h01 HE | Ocean Biomedical, Inc.
Providence, RI, April 13, 2023 (GLOBE NEWSWIRE) -- Ocean Biomedical, Inc. (NASDAQ: OCEA), a biopharma company working to accelerate the development and commercialization of scientifically compelling...
Picture1.png
Ocean Biomedical (NASDAQ: OCEA) Details Novel Malaria Therapeutic Discoveries at the NIH Laboratory of Malaria Vaccinology and Immunology on PfGARP’s Potential as a Highly Effective Vaccine Target and Therapeutic Candidate to Treat Malaria
21 mars 2023 08h01 HE | Ocean Biomedical, Inc.
Providence, RI, March 21, 2023 (GLOBE NEWSWIRE) -- Ocean Biomedical, Inc., a biopharma company working to accelerate the development and commercialization of scientifically compelling assets from...
Picture1.png
Ocean Biomedical, Inc. (NASDAQ: OCEA) Announces Award of New Patent to Scientific Co-Founder Dr. Jake Kurtis for Novel Malaria Vaccine Target
28 févr. 2023 08h01 HE | Ocean Biomedical, Inc.
Breakthrough approach targets stage in malaria lifecycle responsible for all clinical disease and death, has potentially significantly greater efficacy compared with vaccines targeting other stages ...